Hugely promising cancer drug dostarlimab is one step closer to being widely available, after the Food and Drug Administration ...
Sanofi ( (SNY) ) has issued an announcement. Sanofi announced that the FDA has granted Breakthrough Therapy designation to tolebrutinib for treating non-relapsing secondary progressive multiple ...
Sanofi SNY announced that the FDA has granted a Breakthrough Therapy designation to its investigational oral BTK inhibitor, ...
Monroe Carell was a natural fit to offer the new therapy. Its multidisciplinary DMD Clinic, co-directed by Burnette, Soslow ...
The Breakthrough Therapy designation is supported by data from the randomized, open-label phase 2 SOLSTICE trial.
Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis Designation is based on positive results from the HERCULES study in adults with ...
Kura Oncology, Inc.'s partnership and promising AML treatment make it a top stock pick with significant upside potential for ...
With the FDA recently approving a revolutionary treatment aimed at helping those with spinal cord injuries, Schneider's ...